Fighting cancer with next generation cell and gene therapies and a universally compatible CAR/TCR T-cell arming technology platform

Elicera's strengths are based on a deep understanding of how cells and viruses can be genetically engineered to trigger a powerful immune response to cancer.

Di Yu, Head of Technical Operations and co-founder, tells more about Elicera in the film.

About Elicera

iTANK-technology platform

A universal CAR T-cell technology platform, compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

iTANK-platform

Ongoing clinical study

Uppsala University is currently sponsoring an ongoing clinical phase I/II-study with Elicera's oncolytic virus, ELC-100, in neuroendocrine tumors. In addition, a second clinical phase I/II-study with CAR T-cell therapy, ELC-301, in B-cell lymphoma, is under planning.

Technology Pipeline

Scientist working with vaccines in a lab

Company Presentation

See the latest company presentation.

Events and Presentations

Sign up for Press Releases

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.